Press Releases
Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update
Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
Cocrystal Pharma Announces Closing of Private Placement
Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
Cocrystal Announces Board Changes
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
